No Data
UNI HEALTH (02211.HK) will hold a Board of Directors meeting on February 25 to approve the mid-term performance.
Gelonghui reported on February 13 that UNI HEALTH (02211.HK) announced that the Board of Directors will hold a meeting on February 25, 2025, to approve the interim results of the company and its subsidiaries for the six months ending December 31, 2024, and their release, as well as to consider the distribution of an interim dividend, if any.
UNI HEALTH: NOTICE OF BOARD MEETING
China Securities Co.,Ltd.: The "Top Ten Outlooks for 2025" in the Pharmaceutical and Health Industry shows that the vaccine export model is becoming more diversified.
CSC released the "Top Ten Outlook for the Pharmaceutical and Health Industry in 2025."
Special Treat Guangwang (600831.SH): Plans to cancel the holding subsidiary Guangdian Health.
On January 7, Longtu Finance reported that Special Treat Guangwang (600831.SH) announced that the Board of Directors authorized the management to dispose of equity in some underperforming holding subsidiaries with poor development prospects, as well as in associated companies with low relevance and weak control capacity. To this end, the company's holding subsidiary Shaanxi Guangdian Huating Investment Holding Co., Ltd. (referred to as "Guangdian Huating") is liquidating and deregistering its holding company Shaanxi Guangdian Health Industry Co., Ltd. (referred to as "Guangdian Health"). Recently, Guangdian Health received the Deregistration Notification from the Data and Administrative Approval Service Bureau of Lianhu District, Xi'an City, approving the deregistration.
Zhejiang Garden Biopharmaceutical (300401.SZ): Plans to establish a subsidiary in Macau to engage in the research, production, and sales of health-related products.
On December 31, Gelonghui reported that Zhejiang Garden Biopharmaceutical (300401.SZ) announced plans to establish a subsidiary in Macau to expand its domestic and international markets and enhance the company's brand influence and market competitiveness. The establishment of a subsidiary in Macau aims to leverage Macau's international platform, expand both domestic and overseas markets, and enhance the company's brand influence and market competitiveness. Additionally, Macau has a solid industrial foundation and favorable policy environment for the research and development, production, and sales of big health products, which is beneficial for the company's big health business development.
Berry Genomics (000710.SZ) subsidiary plans to invest 26.8 million yuan in Fuzhou Xintou Zhi Kai Ruikang, focusing on the Medical and health sector.
Berry Genomics (000710.SZ) announced that its wholly-owned subsidiary Fujian Berry Health and Genetic Technologies Co., Ltd. (abbreviated...
